Goldman Sachs analyst Michael Lapides downgrades Evergy (NYSE:EVRG) from Buy to Neutral and announces $72 price target.
Piper Sandler Maintains Overweight on Evofem Biosciences
Piper Sandler analyst David Amsellem maintains Evofem Biosciences (NASDAQ:EVFM) with a Overweight.